224
Participants
Start Date
December 31, 2005
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Autologous transplantation using rituxan/BEAM
Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Autologous transplantation using Bexxar/BEAM
Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Medical College, The New York Presbyterian Hospital, New York
University of Rochester Medical Center, Rochester
University of Pennsylvania Cancer Center, Philadelphia
University of Maryland Medical Systems/Greenbaum Cancer Center, Baltimore
Johns Hopkins/SKCCC, Baltimore
Virginia Commonwealth University/MCV Hospital, Richmond
University of North Carolina Hospital at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Cancer Centers of the Carolinas, Greenville
Emory University, Atlanta
University of Florida College of Medicine (Shands), Gainesville
University of Miami, Miami
H. Lee Moffitt Cancer Center, Tampa
Vanderbilt University Medical Center, Nashville
University Hospitals of Cleveland/Case Western, Cleveland
University of Michigan Medical Center, Ann Arbor
University of Iowa Hospitals and Clinics, Iowa City
Medical College of Wisconsin, Milwaukee
University of Wisconsin Hospital and Clinics, Madison
University of Minnesota, Minneapolis
Loyola University Medical Center, Maywood
Washington University/Barnes Jewish Hospital, St Louis
University of Nebraska, Omaha
Baylor University Medical Center, Dallas
Texas Transplant Institute, San Antonio
St. Lukes Mountain States Tumor Institute, Boise
University of Utah Medical School, BMT, Salt Lake City
Intermountain BMT Program, Salt Lake City
Providence Portland Medical Center, Portland
Columbia River Oncology Program, Portland
Fred Hutchinson Cancer Research Center, Seattle
Yale University School of Medicine, New Haven
Tufts-New England Medical Center, Boston
Hackensack University Medical Center, Hackensack
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Cancer Institute (NCI)
NIH
National Heart, Lung, and Blood Institute (NHLBI)
NIH